“Improving Effectiveness of the Tuberculosis Prevention and Control Programs in Resource Limited Countries” | CDC RFA PS14 141104CONT17

Opportunity Information: Apply for CDC RFA PS14 141104CONT17

This grant opportunity, titled "Improving Effectiveness of the Tuberculosis Prevention and Control Programs in Resource Limited Countries," is a U.S. government public health funding announcement administered by the Department of Health and Human Services through the Centers for Disease Control and Prevention (CDC), specifically within CDCs Center for Global Health (CGH). It is focused on strengthening tuberculosis (TB) prevention and control efforts in settings where health systems and program resources are limited, with the overarching intent of improving how well national or subnational TB programs find cases, diagnose disease, treat patients successfully, and reduce ongoing transmission. The opportunity is categorized under health activities and is associated with CFDA number 93.116, which corresponds to CDC global health-related assistance.

The funding mechanism is a cooperative agreement, which typically means the CDC expects to have substantial involvement beyond simply providing funds. In practical terms, recipients generally work closely with CDC technical staff, align activities with CDC guidance and global best practices, and may receive hands-on support related to program design, implementation, monitoring, and evaluation. The opportunity category is listed as continuation, indicating it is intended to continue or extend work that is already underway rather than start an entirely new, unrelated project. The funding opportunity number is CDC RFA PS14 141104CONT17, which signals it is part of an established RFA series and specifically a continuation action under that line of work.

The announcement was created on February 3, 2017, and the original closing date was March 31, 2017. The expected number of awards is 10, suggesting CDC anticipated supporting a set of partners across multiple countries or regions, or multiple implementing organizations working in different contexts. The award ceiling is listed as 0, which commonly indicates that a specific maximum award amount is not provided in the summary field, may vary by recipient, may be determined by available appropriations, or may be detailed elsewhere in the full announcement rather than in the abbreviated record.

Eligibility is described broadly as "Others," with a note to consult the "Additional Information on Eligibility" section for specifics. In CDC global TB opportunities, eligible applicants often include a mix of international and domestic entities such as non-governmental organizations, universities, research institutions, public international organizations, and in some cases ministries of health or other governmental bodies, depending on the particular terms of the announcement. The key point from the listing is that eligibility is not limited to one narrow applicant type, but instead is defined in the detailed eligibility language in the full funding notice.

Programmatically, the stated purpose is improving the effectiveness of TB prevention and control programs in resource-limited countries. While the listing itself provides only the title-level description, TB program effectiveness generally centers on practical, measurable improvements such as increasing timely detection of TB (including harder-to-diagnose forms like pediatric TB and extrapulmonary TB), expanding access to quality-assured diagnostics (for example, rapid molecular testing where feasible), strengthening laboratory and specimen transport networks, improving treatment initiation and completion, reducing loss to follow-up, and strengthening patient-centered approaches that support adherence. In many resource-constrained settings, effectiveness also hinges on the ability of programs to target high-risk groups, integrate TB activities with HIV services where co-infection burdens are high, enhance infection prevention and control in health facilities and congregate settings, and improve the quality of surveillance and case reporting systems so decisions are driven by reliable data.

Because this is a continuation cooperative agreement under CDCs global health portfolio, the work is likely intended to build on existing TB program investments, partnerships, and national strategies. The types of activities typically supported under such efforts include technical assistance to national TB programs; workforce development and training for clinicians, laboratorians, and program managers; quality improvement initiatives to close gaps in diagnosis and care; strengthening supply chain systems for TB medicines and commodities; and monitoring and evaluation to track program performance and outcomes. The cooperative agreement structure implies the recipient would not be operating in isolation, but rather in coordination with CDC and often with host-country governments and other major global TB stakeholders to ensure alignment, avoid duplication, and scale approaches that are shown to work.

In summary, this opportunity is a CDC-run continuation cooperative agreement in the global health space designed to help make TB prevention and control programs work better in resource-limited countries. It anticipated up to 10 awards, was open in early 2017, and targeted improvements in the operational performance and impact of TB programs through CDC-supported collaboration, technical assistance, and evidence-based public health implementation.

• The Department of Health and Human Services, Centers for Disease Control - CGH in the health sector is offering a public funding opportunity titled "“Improving Effectiveness of the Tuberculosis Prevention and Control Programs in Resource Limited Countries”" and is now available to receive applicants.
• Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.116.
• This funding opportunity was created on Feb 03, 2017.
• Applicants must submit their applications by Mar 31, 2017. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
• The number of recipients for this funding is limited to 10 candidate(s).
• Eligible applicants include: Others (see text field entitled Additional Information on Eligibility for clarification).

Apply for CDC RFA PS14 141104CONT17

[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal: